Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition
Conclusions:
These results provide a further insight into the molecular mechanisms affected by crizotinib in ARMS cells inferring that it could be a useful therapeutic tool in ARMS cancer treatment.
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Francesca MegiorniHeather McDowellSimona CameroOlga MannarinoSimona CeccarelliMilena PaianoPaul LostyBarry PizerRajeev ShuklaAntonio PizzutiAnna ClericoCarlo Dominici Source Type: research
More News: Cancer | Cancer & Oncology | Cancer in Adolescents | Children | Genetics | Insulin | Lymphoma | Rhabdomyosarcoma